Astellas Pharma has revised upward its full-year consolidated earnings forecast for the fiscal year ending March 2027. Revenue has been raised to ¥2.33 trillion and operating profit to ¥460 billion, reportedly driven by growth in oncology drugs.
Astellas Pharma revised its full-year earnings forecast upward. Under the new outlook, revenue is expected to reach ¥2.33 trillion and operating profit ¥460 billion.
The previous forecast was revenue of ¥2.22 trillion and operating profit of ¥395 billion, and the latest revision represents an upward adjustment from those levels.
The change is reportedly driven by growth in oncology drugs, presenting a new overall outlook for consolidated earnings for the fiscal year ending March 2027.